ARS Pharmaceuticals (SPRY) executive compensation, 2026 proxy

Richard Lowenthal, President and Chief Executive Officer, was paid $9.7M in 2025, up 35% from $7.2M the year before.

Filed
April 29, 2026
Annual meeting
June 24, 2026
Pay year
2025
Named executives
3
CEO total pay
$9.7M+35% vs prior year
Ending Cash
$245MAs of December 31, 2025
Prescribing Providers
22,500Healthcare providers prescribing neffy

How Lowenthal was paid

$9.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary7%Option awards64%Non-equity incentive3%All other compensation26%

Named executive officers

ExecutiveTotal
Richard LowenthalPresident and Chief Executive Officer$9,656,400
Sarina TanimotoChief Medical Officer$5,290,471
Justin ChakmaChief Business Officer$2,888,109

What changed and why

  • $9.7MChief executive officer total compensation increased to $9,656,400 in 2025 from $7,174,995 in 2024.
  • Option awards comprised the largest portion of executive pay.
  • Cash bonuses were earned based on company and personal objectives.
  • $245MThe company ended 2025 with $245 million in cash and short-term investments.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.